Indivior Pharmaceuticals Inc
INDV
NASDAQ·Healthcare·Drug Manufacturers - Specialty & Generic·Mkt cap $4.4B
$34.93
▲ +0.17%
P/E
12.48
Mkt Cap
$4.4B
52-Wk Range
$22.22–$42.81
52-Week Range
$22.22 - $42.81
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Up 42.0% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
5 reasons
- Market-leading buprenorphine franchise with established brand recognition and physician relationships
- Proprietary extended-release formulations (SUBLOCADE monthly injection) reducing dosing burden and improving patient compliance
- Regulatory moat with FDA approvals and exclusivity protections for core products
- Strategic partnerships with biotech firms (ADDEX, Alar Pharmaceuticals, Click Therapeutics, Aelis Farma) accelerating pipeline innovation
- Focused expertise in addiction medicine and underserved therapeutic areas with high unmet medical needs
Bear Case
1 risk
- Average volatility.
Growth
Stable outlook
Positive revenue trend
Value
Deep value opportunity - significant discount to Biotech & Therapeutics peers
Momentum
Stable
+0.1% over 3m
Quality
Excellent
Strong fundamentals
Dividend
None
No dividend
Smart-money signal
Who's buying INDV right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Latest print - beat on both lines
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Oct 29, 2026
AUG 3, 2026
Reported EPS of $1.15 vs $0.87 consensus (+32.3% surprise). Revenue of $343.0M vs $306.2M expected (+12.0%). Beat on both top and bottom lines.
EPS surprise · last 4Q
1 of 1 beats
Estimate
Actual
Q3 26
+32.3%
Revenue trend · last 8Q
—
+2%
-6%
+1%
+2%
+20%
+19%
+14%
Q3 24
Q4 24
Q1 25
Q2 25
Q3 25
Q4 25
Q1 26
Q2 26
$307.0M
$299.0M
$266.0M
$302.0M
$314.0M
$358.0M
$317.0M
$343.0M
Margins · last 8Q
Gross
85.7%
Operating
46.6%
Profit
35.6%
Wall Street consensus
2 analysts · 100% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
100%
Hold
0%
Sell
0%
Median Price Target
—
Latest: Barclays · Aug 5, 2026
vs Industry
How INDV stacks vs Drug Manufacturers - Specialty & Generic
Stock metrics vs industry averages. Green = better than industry.
Industry comparison data unavailable for this stock.
Related